Compare Keysight Technologies Inc (KEYS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs TransMedics Group Inc — how do they compare? Keysight Technologies Inc trades at $344 (market cap $58.74B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Keysight Technologies Inc is far larger — about 18.9× TransMedics Group Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| KEYS | TMDX | |
|---|---|---|
Market Cap | $58.74B | $3.10B |
Sector | Technology | Technology |
52-Week High | $373.34 | $150.42 |
52-Week Low | $158.51 | $61.99 |
Enterprise Value | $59.08B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $354.38, up 5.66% with strong bullish momentum. The stock shows robust fundamentals with revenue of $5.38B and net income of $850M in 2025, supported by consistent earnings beats. Technical indicators signal bullish trends with moving averages supporting upward momentum, while RSI suggests mild overbought conditions. Recent news highlights institutional buying and product innovations in 5G and photonics.
Outlook remains positive with analyst consensus at Buy (81%) and $396.56 price target, offering ~12% upside. Risks include elevated valuation multiples (P/E 55.35) and competitive pressures in tech instruments. Earnings growth and strategic acquisitions position KEYS for continued strength, though investors should monitor execution on $6.1B revenue guidance for 2026.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
